BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38668051)

  • 21. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
    Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the 5
    Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
    Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.
    Arslan S; Khaled S; Nakamura R
    Cancer Treat Res; 2021; 181():115-132. PubMed ID: 34626358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Childhood myelodysplastic syndrome.
    Chatterjee T; Choudhry VP
    Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
    Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
    J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes: what do hospitalists need to know?
    Zeidan AM; Faltas B; Douglas Smith B; Gore S
    J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress in the diagnosis of and therapy for MDS].
    Nannya Y
    Rinsho Ketsueki; 2016; 57(10):1980-1990. PubMed ID: 27725596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
    Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
    Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
    Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
    Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
    Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
    Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic syndromes current treatment algorithm 2018.
    Steensma DP
    Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
    Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
    Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.
    Acha P; Mallo M; Solé F
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.